A standard lipid panel reports four numbers, and the one that drives most decisions is LDL cholesterol: the National Heart, Lung, and Blood Institute describes LDL below 100 mg/dL as optimal for adults, while the American Heart Association's 2018 cholesterol guideline treats LDL as the primary treatment target because each 39 mg/dL, one mmol/L, reduction in LDL sustained over years cuts major vascular events by roughly a fifth, per the meta-analyses the guideline cites. Nearly 94 million US adults aged 20 or older have total cholesterol above 200 mg/dL, according to CDC estimates, and most have no symptoms to warn them.
This article walks through each number on the panel, the reference ranges health agencies publish, and how clinicians turn those values into risk decisions. Newspaper Daily publishes information, not medical advice; interpretation of any individual panel belongs with a clinician who can weigh personal history.
What does each number on the panel measure?
A standard fasting or non-fasting lipid panel reports total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. LDL, low-density lipoprotein, carries cholesterol into artery walls, where it forms the plaques behind atherosclerosis; this is why it carries the informal label of bad cholesterol. HDL, high-density lipoprotein, transports cholesterol away from tissues and back to the liver, and higher values associate with lower cardiovascular risk in population studies. Triglycerides are fat molecules in the blood, elevated by alcohol, refined carbohydrates, and calories above need.
Total cholesterol is simply the sum of the cholesterol carried in all lipoproteins, which makes it a blunt instrument. A person with high HDL can post a high total with a benign profile, while someone with normal total cholesterol and low HDL can still carry elevated risk. The NHLBI's reference ranges, current as of its 2023 consumer materials, are as follows:
| Measure | Desirable | Borderline | High / undesirable |
|---|---|---|---|
| Total cholesterol | Below 200 mg/dL | 200 to 239 mg/dL | 240 mg/dL and above |
| LDL cholesterol | Below 100 mg/dL | 130 to 159 mg/dL | 160 mg/dL and above |
| HDL cholesterol | 60 mg/dL and above (protective) | — | Below 40 mg/dL in men, below 50 in women |
| Triglycerides | Below 150 mg/dL | 150 to 199 mg/dL | 200 mg/dL and above |
These ranges describe population reference points, not personal targets. A person with established heart disease or diabetes is typically held to an LDL ceiling far below 100, while a healthy 25-year-old may need only reassurance at a mildly elevated value.
Why do thresholds keep shifting across guidelines?
Because the evidence moved. The 2013 AHA/ACC guideline replaced the older treat-to-target framework, which chased fixed LDL numbers, with a risk-based framework: statin intensity is chosen from a person's overall cardiovascular risk, and LDL is then remeasured to confirm the chosen threshold has been met. The 2018 update restored numeric LDL targets for higher-risk groups, for instance below 70 mg/dL for people after certain cardiovascular events, per the AHA/ACC Multisociety Guideline. The thresholds are statements of those bodies' expert synthesis, and they differ modestly from the European cardiology guidelines, which aim lower still.
How is risk actually calculated?
For adults without known cardiovascular disease, the guideline pathway starts with the pooled cohort equations, a calculator using age, sex, race, blood pressure, cholesterol, diabetes, and smoking to estimate the 10-year probability of a heart attack or stroke. The AHA/ACC framework assigns statin therapy to people with diabetes, to anyone with LDL of 190 mg/dL or higher regardless of other factors, and to those whose 10-year risk reaches 7.5 percent or higher after a risk discussion. Clinicians then consider enhancers, including family history of early heart disease, inflammatory conditions, and elevated markers such as apolipoprotein B or lipoprotein(a), the latter now recommended by the NHLBI for at least once-in-a-lifetime measurement under its 2022 guidance.
Related stories: Home Blood Pressure Monitoring: How to Do It and Read the Numbers · Preventing Falls in Older Adults: What Works and Why It Matters.
What about non-fasting panels and new markers?
Fasting is no longer mandatory for most panels: the 2016 European consensus, adopted in practice by many US laboratories, validated non-fasting sampling because lipid values move little after ordinary meals, though triglycerides rise somewhat. When triglycerides come back above 400 mg/dL, a fasting repeat is typically ordered. Additional markers refine the picture in selected people: apolipoprotein B counts the atherogenic particles directly and helps in diabetes or metabolic syndrome; LDL particle number offers a similar refinement; and high-sensitivity C-reactive protein measures inflammation, which guided a subset of statin decisions in the trials reviewed by the AHA.
Can lifestyle changes move the numbers?
Yes, with predictable magnitudes. NHLBI consumer guidance and the AHA's dietary materials describe the following typical effects: replacing saturated fat with unsaturated fat lowers LDL by roughly 10 percent; adding 5 to 10 grams of soluble fiber daily lowers it by around 5 percent; weight loss of 10 pounds can lower LDL meaningfully in people with overweight; aerobic exercise raises HDL modestly, by around 5 percent in many trials; and cutting alcohol and refined sugars is the most effective lever for elevated triglycerides, which can fall dramatically within weeks. Diet and exercise rarely substitute for statins once very high risk is established, but they shift risk across populations, and the AHA notes the combination routinely moves LDL by 20 to 30 percent when followed consistently.
What is familial hypercholesterolemia?
One cause of very high LDL deserves separate mention because it runs in families and often goes unrecognized. Familial hypercholesterolemia, FH, is a genetic condition affecting roughly one in 250 people, per the National Human Genome Research Institute, that impairs the liver's clearance of LDL from the blood. Untreated, it produces LDL values of 190 mg/dL or higher in heterozygous carriers from early adulthood and causes heart disease decades earlier than average, which is why the AHA/ACC guideline treats any LDL above 190 as a trigger for specialist consideration rather than a wait-and-see value. Diagnosis is clinical, based on LDL level, family history of early heart attacks, and physical signs such as tendon thickening, with genetic testing available. The reassuring part is that FH responds to treatment, often with higher-intensity statins plus additional agents, and family cascade screening, testing first-degree relatives once a case is found, identifies affected people while prevention still has decades to work.
When to see a doctor
When to see a doctor
Adults without known heart disease should discuss when to start lipid screening with a clinician; the NHLBI's current guidance favors a first panel between ages 9 and 11, again between 17 and 21, and every four to six years through adulthood. An LDL of 190 mg/dL or higher warrants prompt clinical attention regardless of age, since it suggests possible familial hypercholesterolemia and may trigger family screening. Chest pain, pressure, or tightness, especially with exertion; shortness of breath; pain radiating to the jaw or arm; or sudden weakness or speech difficulty are emergency symptoms, not lipid-panel territory, and require immediate medical care. Finally, muscle aches after starting a statin should be reported rather than endured, because alternatives exist.